{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:12:01Z","timestamp":1779340321363,"version":"3.51.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Colorectal cancer is a globally prevalent malignancy of the digestive system. This systematic review and meta-analysis was conducted to evaluate the safety and effectiveness of bevacizumab combined with the FOLFOX regimen for the treatment of colorectal cancer, with the aim of informing clinical management and improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis was conducted in accordance with PRISMA 2020. PubMed, EMBASE, Web of Science, CNKI, and WanFang Database were systematically searched from database inception to April 30, 2023. Database-specific search strategies were developed using Boolean operators, controlled vocabulary terms where applicable, and free-text keywords related to colorectal cancer, bevacizumab, and FOLFOX-based chemotherapy. Reference lists of relevant studies were manually screened, and grey literature sources and trial registries were also checked when feasible. No language restrictions were applied during the initial search; studies published in English or Chinese were considered for inclusion. Randomized controlled trials comparing FOLFOX plus bevacizumab with FOLFOX alone in patients with advanced or metastatic colorectal cancer were included. Study selection, data extraction, and quality assessment were performed independently by two reviewers, and meta-analysis was conducted using RevMan 5.4 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven randomized controlled trials were included. The pooled analysis showed that bevacizumab plus FOLFOX significantly improved ORR and DCR compared with FOLFOX alone. No significant differences were observed in gastrointestinal reactions, leukopenia, liver injury, neurotoxicity, or hypertension in the overall pooled analysis, although substantial heterogeneity was noted for hypertension and was addressed using a random-effects model. Sensitivity analyses suggested that the main efficacy findings were relatively robust.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bevacizumab combined with the FOLFOX regimen may improve short-term efficacy outcomes, particularly ORR and DCR, in patients with advanced or metastatic colorectal cancer. However, the evidence for long-term survival benefit and quality-of-life improvement remains insufficient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1834867","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:52:34Z","timestamp":1779339154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A meta-analysis on the effectiveness and safety of FOLFOX plus bevacizumab for colorectal cancer treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Weiyin","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Anorectal Surgery, Yiwu Central Hospital","place":["Yiwu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengming","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery, Yiwu Central Hospital","place":["Yiwu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuandong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery, Yiwu Central Hospital","place":["Yiwu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21601","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2019.01.003","article-title":"Pattern, stage, and time of recurrent colorectal cancer after curative surgery","volume":"18","author":"Guraya","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment: a phase 3 randomized controlled trial","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"key":"B9","article-title":"Clinical effects of bevacizumab combined with FOLFOX regimen for patients with advanced colon cancer","volume":"12","author":"Lv","year":"2014","journal-title":"Oncol Prog"},{"key":"B10","article-title":"Clinical study of bevacizumab combined with the FOLFOX4 chemotherapy regimen in the treatment of advanced metastatic colorectal cancer[J]","volume":"31","author":"Zhang","year":"2015","journal-title":"Chin J Clin Pharmacol"},{"key":"B11","article-title":"Clinical efficacy and safety of avastin combined with FOLFOX in the treatment of advanced metastatic colorectal cancer","volume":"31","author":"Xie","year":"2015","journal-title":"Chin J Clin Pharmacol"},{"key":"B12","article-title":"Effect of bevacizumab combined with FOLFOX on the expression of VEGF, MMPs and COX-2 in patients with advanced colorectal cancer","volume":"33","author":"Xiao","year":"2016","journal-title":"J Clin Res"},{"key":"B13","article-title":"Bevacizumab combined with FOLFOX regimen in treatment of patients with advanced colorectal cancer","volume":"23","author":"Lv","year":"2017","journal-title":"Int Med Health Guidance News"},{"key":"B14","article-title":"Clinical effect of bevacizumab combined with MFOLFOX6 in treatment of advanced colon cancer and its effect to serum CEA","volume":"7","author":"Chen","year":"2017","journal-title":"China Med Pharm"},{"key":"B15","article-title":"Treatment of metastatic colon cancer with bevacizumab combined with FOLFOX-6 chemotherapy","volume":"27","author":"Shi","year":"2017","journal-title":"New Med"},{"key":"B16","article-title":"Clinical study on targeted therapy for patients with liver metastasis of colon cancer","volume":"46","author":"Chen","year":"2017","journal-title":"Chongqing Med J"},{"key":"B17","article-title":"Efficacy and safety of bevacizumab combined with FOLFOX in the treatment of metastatic colorectal cancer","volume":"11","author":"Liao","year":"2018","journal-title":"Chin J Clin Rational Drug Use"},{"key":"B18","article-title":"Clinical trial of bevacizumab injection on advanced colon cancer","volume":"34","author":"Luo","year":"2018","journal-title":"Chin J Clin Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/dcr.0000000000001480","article-title":"Differential vant chemotherapy for patients with microsatellite-stable stage III colorectal cancer status: a retrospective analysis","volume":"62","author":"Yamadera","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1096\/fba.2021-00069","article-title":"Inhibition of insulin-like growth factor 2 mRNA-binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics","volume":"4","author":"Betson","year":"2022","journal-title":"FASEB Bioadv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-022-00286-9","article-title":"Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress","volume":"10","author":"Marx","year":"2022","journal-title":"Cancer Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5114\/wo.2020.94728","article-title":"Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy","volume":"24","author":"Cybulska-Stopa","year":"2020","journal-title":"Contemp Oncol (Pozn)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01465-3","article-title":"Phase II study of S-1 on alternate days plus bevacizumab in patients aged \u2265 75 years with metastatic colorectal cancer (J-SAVER)","volume":"24","author":"Moriwaki","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0119","article-title":"aCGH analysis of predictive biomarkers for response to bevacizumab plus oxaliplatin- or irinotecan-based chemotherapy in patients with metastatic colorectal cancer","volume":"24","author":"Fujita","year":"2019","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24276","article-title":"Tumor vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment","volume":"9","author":"Noonan","year":"2018","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2017.10.028","article-title":"Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3","volume":"88","author":"Modest","year":"2018","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1834867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:52:37Z","timestamp":1779339157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1834867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1834867"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1834867","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1834867"}}